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Abstract In Ph− myeloproliferative neoplasms, the quantifi-
cation of the JAK2V617F transcripts may provide some advan-
tages over the DNA allele burden determination. We developed
a q-RT-PCR to assess the JAK2WT and JAK2V617F mRNA
expression in 105 cases (23 donors, 13 secondary polycythe-
mia, 22 polycythemia vera (PV), 38 essential thrombocythemia
(ET), and 9 primary myelofibrosis (PMF)). Compared with the
standard allele-specific oligonucleotide (ASO)-PCR technique,
our assay showed a 100 % concordance rate detecting the
JAK2V617F mutation in 22/22 PV (100 %), 29/38 (76.3 %)
ET, and 5/9 (55.5 %) PMF cases, respectively. The sensitivity
of the assay was 0.01 %. Comparing DNA and RNA samples,
we found that the JAK2V617F mutational ratios were signifi-
cantly higher at the RNA level both in PV (p =0.005) and ET
(p =0.001) samples. In PV patients, JAK2WT expression levels
positively correlated with the platelets (PLTs) (p =0.003)
whereas a trend to negative correlation was observed with the
Hb levels (p =0.051). JAK2V617F-positive cases showed the
lowest JAK2WT and ABL1 mRNA expression levels. In all the
samples, the expression pattern of beta-glucoronidase (GUSB)
wasmore homogeneous than that ofABL1 orβ2microglobulin
(B2M). Using GUSB as normalizator gene, a significant in-
crease of the JAK2V617F mRNA levels was seen in two ET
patients at time of progression to PV. In conclusion, the pro-
posed q-RT-PCR is a sensitive and accurate method to quantify
the JAK2 mutational status that can also show clinical correla-
tions suggesting the impact of the residual amount of the
JAK2WT allele on the Ph− MPN disease phenotype. Our
observations also preclude the use of ABL1 as a housekeeping
gene for these neoplasms.
Keywords Ph− myeloproliferative neoplasms . JAK2WT
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Introduction
Philadelphia chromosome-negative myeloproliferative neo-
plasms (Ph− MPNs) are clonal myeloid disorders characterized
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by an increased production of terminally differentiated cells.
Themechanisms ofMPN initiation and progression have been
extensively studied. A number of genetic and epigenetic ab-
normalities associated with Ph− MPNs have been reported
[1–5]. The somatic mutation of JAK2V617F is the most
frequent genetic alteration in these diseases and is presently
considered as a major diagnostic criterion for Ph− MPNs. The
frequency of this mutation is greater than 95% in patients with
polycythemia vera (PV) and around 50 % in patients with
essential thrombocythemia (ET) or primary myelofibrosis
(PMF).
JAK2V617F-positive Ph− MPNs show a biological con-
tinuum with clinical presentation, which is in part influenced
by the JAK2V617F mutational load [6]. A relationship be-
tween JAK2V617F mutational burden and disease phenotype
has been reported [7].
Although the clinical relevance of the correct quantification
of the JAK2 allele burden is still not clearly stated, the JAK2
tyrosine kinase activity is now a therapeutic target for inno-
vative and more specific treatment of these diseases [8]. The
still debated pathogenesis of MPNs forces to seek methods
which are increasingly specific and sensitive for the quantifi-
cation of the JAK2 allele burden at diagnosis and during
treatment. To date, the detection and quantification of the
JAK2WT and JAK2V617F alleles are usually assessed using
genomic DNA. However, the quantification of JAK2V617F
mRNA transcripts by a real-time quantitative RT-PCR (q-RT-
PCR) may provide some advantages over the DNA allele
burden [9]. In PV mononuclear cell samples, Zhao et al. [10]
demonstrated that the ratio JAK2V617F/JAK2WT is higher in
cDNA than in genomic DNA. Using an ARMS assay on
cDNA originated from granulocyte mRNAs, Vannucchi
et al. [11] identified more JAK2-mutated transcripts in MPN
patients (9 %), as compared to conventional allele-specific
PCR. Moreover, the mRNA (but not DNA) can be extracted
from platelets present in buffy coats, and this may increase the
JAK2V617F assay sensitivity in ET patient samples. Finally,
in transgenic mice models, the JAK2V617F transcript levels
were found to be strictly correlated with the Ph− MPN
phenotypes [12]. By contrast, q-RT-PCR requires a parallel
amplification of a housekeeping gene (HKG) as control gene
(CG) to correct variations in RNA quality and quantity and to
calculate the sensitivity of each measurement. Therefore, to
better investigate the pathogenesis complexity of the Ph−
MPNs and to provide a useful assay to monitor minimal
residual disease (MRD), we set up an absolute q-RT-PCR
method for the quantification of JAK2WT and JAK2V617F
mRNA. The data herein reported show that this method is
highly specific and sensitive. Moreover, the observation of a
significant variability within the sample groups of the expres-
sion levels of ABL1 , one of the most commonly used HKGs,




Peripheral blood buffy coat specimens were collected from
105 individuals. Twenty-two of them were diagnosed as hav-
ing PV, 38 ET, and 9 PMF according to the 2008 WHO
diagnostic criteria [13]. Thirteen patients with secondary poly-
cythemia (SP) and 23 healthy blood donors were included as
controls. For three patients with initial diagnosis of ET who
progressed to PV, paired samples of both disease phases were
available. All specimens were collected after patients had
signed an informed consent. The study was approved by our
IRB at AUSL Latina (no. 6315/A001/2012).
DNA, RNA extraction, and cDNA synthesis
Cell pellets were either processed for DNA purification using
the Wizard Genomic DNA Purification Kit (Promega Corpo-
ration, Madison,WI), according to the manufacturer’s instruc-
tions, or resuspended in guanidine isothiocyanate for RNA
extraction [14, 15]. Equal amounts of RNA (1 μg) were
reverse transcribed into cDNAs with random hexamers and
MuLV reverse transcriptase (Applied Biosystems, Monza,
Italy).
JAK2V617F mutation analysis and allele burden assay
JAK2V617F mutation was detected in DNA samples using
the allele-specific PCR method previously described by Bax-
ter et al. [16] The quantification of JAK2V617F allele burden
on genomic DNA was performed using the JAK2V617F
the manufacturer’s instructions.
Allele-specific q-RT-PCR
To obtain reference curves, standard plasmids were
manufactured to contain JAK2WT or JAK2V617F cDNA se-
quences. cDNAs were obtained from RNA extracted from hu-
manK562 cells (homozygous for JAK2WT allele) andHEL cells
(homozygous for JAK2V617F allele). We designed specific
primers (forward: TTCTGGATAAAGCACACAGAAA; re-
verse: CCAAATTTTACAAACTCCTGAACC), in order to am-
plify 150 bp including theV617F codon (NM_004972.3:c.1745-
1895), using the Primer 3 software (http://www.bioinformatics.
nl/cgi-bin/primer3plus/primer3plus.cgi). One-step cloning strate-
(Invitrogen, Monza, Italy). Each plasmid vector was checked
by sequencing and includes five 10-fold serial dilutions, rang-
ing from 105 to 10 targets per well.
JAK2WT and JAK2V617F mRNAs were measured as
described by Merker et al. [17]. Primers and probe
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MutaQuant® Allele kit (Qiagen, Milano, Italy), according to
gy was performed by using the TOPO TA Cloning® kit
concentrations were optimized at concentrations of 300 and
200 nM, respectively, in a final volume of 25 μl. q-RT-PCR
was performed in the ABI 7900 (Applied Biosystems) with an
initial 10-min incubation at 95 °C, followed by 40 cycles of
15 s at 95 °C and 1 min at 60 °C. All samples and no-template
controls were run in triplicates.
For each sample, the ABL1 , B2M , and GUSB copy num-
bers were determined by using standard endogenous plasmid
ing to the manufacturer’s instructions and in accordance with
the Europe Against Cancer (EAC) network [18].
JAK2 mutational burden evaluation
The mutational burden ratio of JAK2 was calculated using the
DNA and RNA copy numbers according to the following
formula: JAK2V617F /(JAK2V617F +JAK2WT).
Statistical analysis
Statistical analyses and graphs were generated using SPSS-10
software. Further, targeted pairwise comparisons to evaluate
the significance between individual diseases were performed
by the two-sided Student’s t test. Results were expressed as
means ± SEM. The level of significance from t test was p <
0.05.
Results
Using the standard qualitative allele-specific oligonucleotide
(ASO)-PCR method [17], the JAK2V617F was detected in
22/22 PV (100 %), in 29/38 (76.3 %) ET, and in 5/9 (55.5 %)
PMF cases, respectively (Table 1). Our q-RT-PCR method
confirmed the presence/absence of the JAK2V617F mutation
in all the cases, resulting in a 100 % concordance rate with the
standard assay. In addition, we did not observe nonspecific
amplification in either JAK2WT or JAK2V617F plasmids or
in positive or negative controls and JAK2V617F-positive and
negative samples (Fig. S1 A, B). cDNA carrying a
predetermined JAK2V617F copy number was diluted with
cDNA from a healthy control to establish the sensitivity of
our q-RT-PCR method. Serial dilution experiments demon-
strated a detection limit of 0.01 % (Fig. S2 A, B).
The main demographic, clinical, and laboratory character-
istics of donors and patients, grouped according to initial
diagnosis, together with their JAK2WT, JAK2V617F, ABL1 ,
B2M , and GUSB median absolute copy numbers are reported
in Table 1. Several lines of evidence demonstrate that the
transition between PV, ET, and PMF is frequent in
JAK2V617F-positive Ph− MPN patients, suggesting for the-
se disease entities a biologic continuum [6]. Therefore, the
analysis of the expression levels of the JAK2WT, ABL1 , B2M ,
and GUSB genes was done, grouping Ph− MPN cases ac-
cording to the presence/absence of the JAK2V617F mutation.
The median of absolute JAK2WT mRNA copy numbers
detected in the donor, SP, and JAK2V617F -positive and
JAK2V617F -negative Ph− MPN groups is depicted in
Fig. 1a. JAK2V617F-positive patients presented a significant-
ly lower JAK2WT mRNA expression compared with donors
and SP and JAK2V617F -negative patients (p =0.002; p<
0.001; p< 0.001, respectively). Significantly higher
JAK2V617F mRNA expression levels were detectable in
PMF patients when compared with ET cases; differences
between PV and ET samples were not statistically significant
(Fig. 1b).
In a group of 12 PV, 17 ET, and 3 PMF, we matched the
JAK2V617F mutational ratios, in patient-derived DNA and
RNA samples. As shown in Fig. 2, with respect to DNA,
ratios were significantly higher when assessed at the RNA
level both in PV (p =0.005) and ET (p =0.001) samples and
not statistically significant in PMFs (three cases). The com-
parisons of the DNA or RNA JAK2V617F mutational burden
ratios showed significant differences whether they were cal-
culated at the DNA or RNA level. At the DNA level, ET
patients showed significantly lower JAK2V617F allele burden
ratios as compared to both PV and PMF (22 % vs. 45 % and
vs. 47 %, respectively [ET vs. PV p =0.01; ET vs. PMF p =
0.02]) whereas, at the RNA level, significant differences were
recorded only between ET and PMF patient groups (56 vs.
80 %; p =0.03) (Fig. 2).
We did not observe significant associations correlating the
JAK2WT or JAK2V617F expression levels and Hb, PLTs,
WBC, splenomegaly, or occurrence of thrombosis in the entire
patient group. Instead, considering the sole PV group, we
observed a positive statistically significant correlation be-
tween the JAK2WT expression levels and PLT count (R2=
0.39; p =0.003) and a trend to negative correlation between
the JAK2WT expression levels and the Hb levels (R2=0.10;
p =0.051) (Fig. 3a, b).
We also found that the ABL1 gene was not uniformly
expressed among healthy donors and patient groups, being
expressed at higher levels in donors and SP and JAK2V617F-
negative patients compared to JAK2V617F -positive cases
(Fig. 4a). A significant positive correlation between the copy
numbers of ABL1 and JAK2WT was measured in
JAK2V617F-positive patients (Fig. 4b). These observations
raise several doubts about the appropriateness of using ABL1
as CG in Ph− MPN patients. Therefore, to identify CGs more
suitable than ABL1 , using the q-RT-PCR protocols optimized
by the EAC program, we evaluated the B2M and GUSB
expression levels in a group of 68 samples (donors=11, SP=
5, PV=16, ET=31, and PMF=5) with remaining available
RNA. Both B2M andGUSB showed similar expression levels
within all the groups examined. However, GUSB showed the
most homogeneous medians and the narrowest distribution of
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controls (FusionQuant® Standards Ipsogen, Qiagen), accord-
values also in the JAJ2V617F -positive cases (Fig. 5a, b)
where the expression levels of ABL1 were significantly af-
fected. In 11 control samples, we assessed the Ct values of
ABL1 , B2M , GUSB , and JAK2 genes. In all cases, the vari-
ations in Ct values turned out to be comparable, and all fell
within three Ct values. However, the Ct values of B2M were
lower than those of ABL1 , GUSB , and JAK2 , thus indicating
the higher level of expression of B2M in these samples
(Fig. S3).
In three ET patients, who progressed to PV during this
study, we could serially assess at ET diagnosis and PV pro-
gression the DNA and RNA JAK2V617F mutational ratios
and the JAK2V617F expression levels normalized with GUS .
The clinical–biologic parameters of these three patients are
reported in Table 2. As illustrated in Fig. 6, we observed a
significant increase of the JAK2V617F expression levels at
PV progression in two of the three cases (case 1 and 3, Fig. 6c)
and a trend toward statistical significance in the remaining
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Fig. 1 JAK2WT and
JAK2V617F mRNA expression
levels detected by q-RT-PCR
method. a JAK2WT absolute
copy numbers, in donors, SP
cases, and Ph− MPN patients. b
JAK2V617F absolute copy
numbers in JAK2V617F-positive
Ph− MPN patients. Circles
indicate the outlier values.
Asterisks indicate the extreme
values
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case. By contrast, the JAK2 mutational ratios at DNA and
RNAwere increased only in case 1 (Fig. 6a, b and Table 2).
Discussion
Our study shows that, in the diagnostic approach toPh− MPN
patients, a q-RT-PCR assay to detect JAK2V617F expression
levels offers comparable specificity than ASO-PCR and allele
burden quantitative assays. Moreover, this method is probably
more sensitive than these “standard”methods, as supported by
the fact that the JAK2V617F mutational ratios were steadily
superior at the RNA than at the DNA level in all the groups
studied. These latter findings, showing an impact of the type
of nucleic acid on the determination of the JAK2V617F bur-
den, are in apparent contrast to those reported by Vannucchi
et al. [11] who did not see differences with respect to the use of
RNA or DNA. A likely explanation of these discrepancies
may rely on the fact that we used buffy-coat preparations,
which include platelets instead of the isolated leukocytes.
These findings might also suggest that, using RNA, it is
possible to avoid the cost-effective and time-consuming
methods for leukocyte isolation.
The higher sensitivity to detect the JAK2V617F mutation at
the RNA level was firstly demonstrated by the above
mentioned study of Vannucchi et al. [11], who reported an
increased percentage (9 %) of JAK2-mutated ET patients by
using RNA instead of DNA. Thus, the mRNA template should
be recommended for the diagnosis of ET patients, usually
presenting a lower JAK2V617F allele burden, or in the moni-
toring of Ph− MPN treatment response.
The present q-RT-PCR method was derived from that
recently proposed by Merker et al. [17] for the quantification
of the JAK2WT and JAK2V617F transcript levels in Ph−
MPNs. However, after testing more than 100 samples of
patients with and without Ph− MPNs, these authors reported
a low level of nonspecific amplifications in samples contain-
ing a high copy number of standard plasmids and in blood
specimens from patients without Ph− MPNs. To eliminate
these undesired amplifications, Merker et al. [17] established a
mutant to wild type cutoff of <0.0005.We optimizedMerker’s
amplification reaction by reducing the amount of final con-
centrations of primers from 800 to 300 nM and of probes to
400 to 200 nM, respectively. We did not observe nonspecific
amplifications in JAK2WT or JAK2V617F reaction by using
plasmid standards, K562 and HEL cell lines, or JAK2V617F-
positive and negative samples, tested as positive or negative
controls (Fig. S1 A, B). The lack of nonspecific amplifications
justifies the use of this test for diagnostic purposes.
Although the analysis of DNA is in principle technically
simpler than that of RNA, discrepant results are often reported
even after DNA-based techniques, so that Lippert et al. [19]
have emphasized the need of using positive and negative
quality controls, and calibration to a reference standard to
improve reproducibility. More recently, the European Leuke-
mia Net/MPN&MPNr-EuroNet group, to avoid that the vari-
ations in the performance of the plethora of qPCR assays
routinely used to detect JAK2V617F could potentially impact
on their clinical utility, selected the most sensitive and
performing of nine DNA-based quantitative PCR assays as
the optimal quantitative-polymerase chain reactionmethod for
routine diagnosis and tracking of minimal residual disease in
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Fig. 2 JAK2V617F mutational burden ratio, calculated at the DNA and


















































BAFig. 3 Correlations between the
JAK2WT expression levels and
PLT count (a) and Hb levels (b)
in the PV patient group
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Unlike reports measuring DNA levels, we did not detect
higher JAK2V617F mRNA expression levels in samples from
ET patients with respect to PV. One possible explanation of
this discrepancy may be that the higher sensitivity of the
present q-RT-PCR method, by increasing the JAK2V617F
copy numbers detected in ET samples, has canceled this
difference.
To evaluate the putative prognostic value of the JAK2WT
and JAK2V617F expression levels detected by the present
assay, we search for significant correlations with the patient’s
clinical–biologic parameters. The relatively small number of
cases did not allow us to draw conclusive remarks on this
issue. However, it is interesting to note that in PV patients, we
observed a significant correlation between the JAK2WT ex-
pression levels and PLT count and a trend to a negative
correlation with the Hb values. These latter findings may
confirm the assumptions that even the residual amount of
the normal JAK2 allele may impact on the different Ph -
negative MPN entities [21].
Aiming to set up a sensitive q-RT-PCR method allowing
the quantification of gene expression, and having to compen-
sate for potential variability of this procedure, we firstly used
ABL1 as HKG. However, we found that the ABL1 gene was
not uniformly expressed among donor and JAK2V617F-neg-
ative and positive patient groups, being significantly lower in
the group characterized by the JAK2V617F mutation. This
finding clearly contradicts the most important requisite of a
HKG that should be expressed at a similar level in all the
tested samples. Therefore, although ABL1 is one of the most
commonly used HKG in hematologic neoplasms [22], at least
in Ph− MPNs, it should not be chosen for gene expression
analysis. To identify CGs more suitable than ABL1 , we eval-
uated two other widely used HKGs as B2M and GUSB . Both
these genes showed similar expression levels within all the
groups examined, but GUSB showed the most homogeneous
medians and the narrowest distribution of values also in the
JAK2V617F-positive cases (Fig. 4). Moreover, we confirmed
that in control samples, JAK2 , ABL1 , and B2M and GUSB
have comparable Ct variations, falling in all cases within three
values and that B2M , compared to the other three genes, is
clearly overexpressed (Fig.S3). The fact that these latter data
exactly reproduced those achieved by the EAC program in a
much larger number of cases than ours confirmed their reli-
ability. Based on these observations, we would suggest
GUSB , but not ABL1 , as the most appropriate GC for this
clinical setting.
The observed positive correlation between the expression
levels of JAK2WT and ABL1 in the JAK2V617F -positive
patient group further suggests the issue that JAK2V617F-
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Fig. 4 a ABL-1 absolute copy
numbers in donors, SP cases, and
Ph− MPN patients grouped
according to the presence/absence
of the JAK2V617F mutation.
Circles indicate the outlier values.
The asterisks indicate the extreme
values. b Correlation between the
ABL-1 and JAK2WT expression
levels in the JAK2V617F-positive
Ph− MPN patient group
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GUSBBAFig. 5 B2M (a) and GUSB (b)absolute copy numbers in donors,
SP cases, and Ph− MPN patients
grouped according to the
presence/absence of the
JAK2V617F mutation. The circle
indicates the outlier values. The
asterisks indicate the extreme
values
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In addition, this finding may support the model recently
proposed by Irino et al. [23]. These authors, focusing on genes
involved in the JAK-STAT signaling pathway, identified two
upregulated genes in MPN patients: SOCS3 , a known target
of the JAK-STAT axis and a potentially novel target, and
SPI1 , encoding PU.1 . The latter gene is a regulator of prolif-
eration and differentiation of hematopoietic cells [24]. The
pathogenic effect of JAK2 mutation appears mediated, at least
in part, through the upregulation of PU.1. In addition, they
showed that PU.1 is regulated by both JAK2 and ABL1 , and
suggested that SOCS3 and PU.1 are common downstream
targets of both JAK2 and ABL1 . Together, these observations
and our results link the constitutive activation of JAK2 to the
downregulation of the expression of ABL1 .
The potential usefulness of GUSB as CG might also be
supported by the additional findings observed in the three ET
patients who progressed to PV. The serial monitoring of the
DNA and RNA JAK2V617F mutational ratios and the
JAK2V617F expression levels normalized with GUSB
allowed to observe a significant increase of the JAK2V617F
expression levels at PV progression in two of the three cases
(case 1 and 3, Fig. 6c) and a trend toward statistical
significance in the remaining case. By contrast, the JAK2
mutational ratios at DNA and RNA were increased only in
case 1 (Fig. 6a, b). These data support in humans the findings
recently demonstrated in transgenic mice showing that the
levels of JAK2V617F expression influence the Ph− MPN
phenotype: higher levels favor erythrocytosis whereas lower
levels favor thrombocytosis [12]. Similarly, Barosi et al. ob-
served a progression toward JAK2V617F homozygosity in
serial DNA samples collected from 64 patients with PMF
[25].
In conclusion, the q-RT-PCR assay hereby reported is a
sensitive and accurate method to quantify the JAK2 mutation-
al status that can also show clinical correlations suggesting the
impact of the residual amount of the JAK2WT allele on the Ph
− MPN disease phenotype. In addition, for the first time, we
provided evidences that ABL1 is not a useful CG to obtain
reliable JAK2V617F quantifications in Ph− MPN patients
whereas GUSB turned out be more appropriate for this pur-
pose. These findings might become clinically relevant in light
of the availability of several new and effective targeted ther-
apies which require sensitive and precise assessment of the
patient’s response to treatments.
Table 2 The hematologic characteristics of the three ET patients who progressed to PV referred at the time of ET diagnosis and at PV progression (pPV)
Characteristics Case 1 Case 2 Case 3
ET pPV ET pPV ET pPV
WBC (1×109/l), median (range) 9.9 26.2 7.1 12 9.2 10.69
PLTs (1×109/l), median (range) 696 1,003 1,184 1,500 519 516
Neutrophils (1×109/l), median (range) 7.5 21 5.6 7.6 5.4 6.73
JAK2WT copy number (1×103), mean ± SEM 5.8±0.7 1±0.01 5.4±0.25 3.7±0.2 3.2±0.08 7.1±1
JAK2V617F copy number (1×103), mean ± SEM 1.3±0.3 5.7±0.5 2.6±0.1 3.6±0.6 4.1±0.5 10.2±0.3
DNA mutational burden ratio 22 69 29.4 28 24 21
mRNA mutational burden ratio 18 85 32 49 56 59
B2M copy number (1×103), mean ± SEM 1,751±27 2,256±500 1,974±75 1,953±71 1,376±142 1,749±163























































Fig. 6 The JAK2V617F
mutational burden ratio in the
three ET patients who progressed
to PVevaluated by the following
three different methods: a the
absolute allele-specific PCR, b
the present absolute allele-
specific q-RT-PCR, and c using
GUSB to normalize the values
achieved by the present q-RT-
PCR assay
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